About Satiogen
Satiogen is a company based in San Diego (United States) founded in 2007 by Andrew Young and Bronislava Gedulin was acquired by Mirum Pharmaceuticals in May 2022. Satiogen has raised $700 thousand across 1 funding round from investors including Mirum Pharmaceuticals and Mesa Verde Venture Partners. Satiogen operates in a competitive market with competitors including Kriya Therapeutics, Sana Biotechnology, Semma Therapeutics, Cellino and Adocia, among others.
- Headquarter San Diego, United States
- Founders Andrew Young, Bronislava Gedulin
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$700 K (USD)
in 1 rounds
-
Latest Funding Round
$700 K (USD), Series A
Apr 15, 2008
-
Investors
Mirum Pharmaceuticals
& 1 more
-
Employee Count
Not available
-
Acquired by
Mirum Pharmaceuticals
(May 23, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Satiogen
Satiogen has successfully raised a total of $700K through 1 strategic funding round. The most recent funding activity was a Series A round of $700 thousand completed in April 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Satiogen
Satiogen has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Mirum Pharmaceuticals and Mesa Verde Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Small molecule therapeutics are developed for rare diseases treatment.
|
Locked | Locked | Locked |
Investor details for Satiogen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Satiogen
Investment portfolio details for Satiogen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Satiogen
Detailed financials for Satiogen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Satiogen Comparisons
Peer comparison for Satiogen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Satiogen
Satiogen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Sana Biotechnology, Semma Therapeutics, Cellino and Adocia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Pendulum is focused on developing advanced probiotic solutions.
|
Detailed competitors of Satiogen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Satiogen
Complete news archive for Satiogen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Satiogen
Satiogen was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Satiogen is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Dan Wood is the current CEO of Satiogen.
Satiogen is a funded company, having raised a total of $700K across 1 funding round to date.
Satiogen Pharmaceuticals has discovered a metabolic mechanism of action termed the bile acid brake that is a novel target for treating type 2 diabetes and obesity without intervention by systemically absorbed pharmaceuticals or invasive surgical methods. Preclinical experiments testing several drugable concepts have demonstrated metabolic effects comparable to marketed drugs, and a clinical study has extended these findings to humans. Preclinical experiments are also underway with a non-surgical device designed to replicate the benefits of gastric bypass surgery.
Satiogen's top competitors include Sana Biotechnology, Semma Therapeutics and Adocia.
Satiogen has 2 investors. Key investors include Mirum Pharmaceuticals, and Mesa Verde Venture Partners.